Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Expectations By $0.08 EPS

Royalty Pharma (NASDAQ:RPRX) released its earnings results on Wednesday. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08, Zacks reports. The company had revenue of $631.00 million during the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a return on equity of 29.49% and a net margin of 33.88%.

Here are the key takeaways from Royalty Pharma’s conference call:

• Royalty Pharma reported a strong Q1 with portfolio receipts up 10% and royalty receipts up 13%, delivered ~14% ROIC and ~20% ROIE, repurchased 1M shares for $50M, raised the 2026 guidance, and increased the dividend by 7%.
• The company is aggressively scaling R&D co-funding with Global Biopharma — announcing J&J and Teva deals totaling ~$1B this quarter — positioning to capture demand from an industry with >$1T projected R&D spend over five years.
• Material portfolio catalysts include Revolution Medicines’ daraxonrasib Phase III that nearly doubled overall survival in 2L pancreatic cancer, FDA approval of Denali’s Avlayah, and acquisition of a royalty on Ziihera (management cites >$2B peak sales potential and low‑double digit unlevered IRR).
• Financial flexibility remains strong with $586M cash, ~$722M portfolio cash flow in Q1, $9.2B of long‑dated investment‑grade debt (12‑yr avg duration), an undrawn $1.8B revolver and a recent Fitch upgrade to BBB, giving ~ $4B+ access to capital.
• Near‑term risks include lower expected milestones (from $128M in 2025 to ~$60M in 2026), headwinds from Promacta LOE, potential US biosimilar TYSABRI and IRA impacts, and an arbitration with Vertex now expected to resolve around mid‑2027.

Royalty Pharma Stock Up 1.2%

NASDAQ RPRX traded up $0.59 on Friday, reaching $50.79. The stock had a trading volume of 3,764,589 shares, compared to its average volume of 3,543,437. Royalty Pharma has a 1 year low of $32.15 and a 1 year high of $51.65. The business has a 50 day moving average price of $47.62 and a 200 day moving average price of $42.75. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $29.30 billion, a price-to-earnings ratio of 34.55, a P/E/G ratio of 3.24 and a beta of 0.40.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $0.235 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.9%. Royalty Pharma’s payout ratio is 63.95%.

Analyst Ratings Changes

RPRX has been the topic of several recent analyst reports. Morgan Stanley upped their price target on Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. UBS Group upped their target price on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. JPMorgan Chase & Co. increased their price target on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Weiss Ratings upgraded shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $53.71.

Insider Activity

In related news, CFO Terrance P. Coyne sold 34,791 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total value of $1,731,895.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 139,164 shares of company stock worth $6,624,902. 18.84% of the stock is owned by insiders.

Institutional Trading of Royalty Pharma

Several large investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC increased its stake in shares of Royalty Pharma by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 446 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 306 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in Royalty Pharma by 59.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,405 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 524 shares in the last quarter. Transamerica Financial Advisors LLC boosted its holdings in Royalty Pharma by 10.7% in the fourth quarter. Transamerica Financial Advisors LLC now owns 5,158 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 498 shares in the last quarter. Finally, Hilltop Holdings Inc. acquired a new position in Royalty Pharma during the third quarter worth $205,000. 54.35% of the stock is owned by institutional investors.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.